OS Therapies Incorporated OSTX 深 滬
等待開盤 05-20 09:30:00 美东时间
1.76
+0.030
+1.73%
華盛通- 最 高1.815
- 今 開1.74
- 成交量 50.37万股
- 最 低 1.6801
- 昨 收 1.73
- 總市值 7.40万
- 52周最高 2.57
- 市盈率 靜 --
- 換手率 1198.15%
- 52周最低 1.15
- 委 比 95.92%
- 總股本 4.20万
- 歷史最高 7.00
- 量 比 0.48
- 振 幅 7.80%
- 歷史最低 1.12
- 每 手 1
- 風險率 0.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高1100美元，花旗、瑞穗、 Melius Research齐上调美光目标价；X-Energy获大小摩等多家机构首予“买入”评级
今日重点评级关注：TD Cowen：维持Strategy"买入"评级，目标价从395美元升至400美元；摩根士丹利：维持Cipher Digital"超配"评级，目标价从40.5美元升至42.5美元
今天 11:55
Lake Street Maintains Buy on OS Therapies, Lowers Price Target to $13
Lake Street analyst Chad Messer maintains OS Therapies (AMEX:OSTX) with a Buy and lowers the price target from $14 to $13.
05-19 22:05
Earnings Scheduled For May 18, 2026
Companies Reporting Before The Bell • Compugen (NASDAQ:CGEN) is likely to repor...
05-18 19:11
OS Therapies Q1 EPS $(0.27) Misses $(0.18) Estimate
OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.18) by 50 percent. This is a 50 percent decrease over losses of $(0.18) per share from the same
05-18 18:37
OS Therapies Says EMA's CAT Initiates Continuous Evaluation Of OST-HER2 CMA Request Regulatory Dossier For Prevention Of Recurrence In Fully Resected, Pulmonary Metastatic Osteosarcoma
Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune pharmacodynamic biomarker response (seroconversion) data and review regulatory successes validating the OST-HER2
04-30 18:10
OS Therapies Files New Patent Application Covering Immune Signature In Response Therapeutic Candidates Developed Using Listeria Monocytogenes Platform
New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular immune responsesCompany to host conference call later in April 2026
04-16 19:27
OS Therapies Q4 EPS $(0.41) Misses $(0.13) Estimate
OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.13) by 228 percent. This is a 70.83 percent decrease over losses of $(0.24) per share from the
03-31 19:54
OS Therapies Engages Four Global Regulators In Q2 2026 Ahead Of Phase 3 Osteosarcoma Trial Enrollment Expected To Begin In Australia
Meetings with all four regulatory agencies scheduled to occur in the second quarter of 2026, with expected Phase 3 commencement in the third quarter of 2026 initially in AustraliaCommencing the Phase 3 confirmatory study
03-27 18:09
OS Therapies Advances OST‑HER2 Toward BLA; FDA Elevates Meeting To Type B Pre‑BLA
FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussionsOS Therapies on track to complete clinical data submission by the end of Q1 2026New York, New
03-09 19:45
OS Therapies Begins FDA Filing for Experimental Cancer Treatment Aimed at Osteosarcoma Recurrence
OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today announced that it has formally initiated a Biologics License Application (BLA) submission
02-02 19:02
